In conclusion, patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation and have less hypoglycemia when compared to patients starting NPH insulin. The gene discussed is DPP4; the disease is Hypoglycemia.